151 related articles for article (PubMed ID: 38272704)
1. First-in-Human Evaluation of Site-Specifically Labeled
Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
4. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
5. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
7. Imaging of HER2 with [
Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
[No Abstract] [Full Text] [Related]
8. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for
O'Donoghue JA; Lewis JS; Pandit-Taskar N; Fleming SE; Schöder H; Larson SM; Beylergil V; Ruan S; Lyashchenko SK; Zanzonico PB; Weber WA; Carrasquillo JA; Janjigian YY
J Nucl Med; 2018 Jan; 59(1):161-166. PubMed ID: 28637800
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Response Monitoring with
Kang M; Shin JI; Han S; Kim JY; Park J; Kim KI; Kang JH; Lee TS
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890234
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
12. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Photoaffinity Bioconjugation for the Creation of
Delaney S; Nagy Á; Karlström AE; Zeglis BM
Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
[TBL] [Abstract][Full Text] [Related]
14. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
15. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
[TBL] [Abstract][Full Text] [Related]
16. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to assess safety, biodistribution and radiation dosimetry for
Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Evaluation of Antibody Modification and
Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
